STOCK TITAN

Kraig Biocraft Laboratories Issues a Letter to Shareholders on Recent Advancements and Potential Recombinant Spider Silk Deliveries in 2025

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Kraig Biocraft Laboratories (KBLB) issued a shareholder letter detailing significant advancements in their spider silk technology. The company has developed a new production strain for their double hybrid system, expected to improve silk production rates by over 25% monthly. Their current BAM-1 single hybrid system, introduced in 2024, has shown substantial improvements in robustness and silk production, matching the resilience of Chinese commercial silk hybrids. The company has stockpiled several hundred kilograms of cocoons in Q1 2025 and plans to include cocoon inventory in future work-in-progress reporting. KBLB is preparing for commercial deliveries to three major global brands in the second half of 2025: a luxury fashion brand, a high-end performance sportswear company, and a top-5 athletic equipment producer, all of whom have expressed commitment through quotes or approved budgets.
Kraig Biocraft Laboratories (KBLB) ha pubblicato una lettera agli azionisti in cui illustra importanti progressi nella loro tecnologia della seta di ragno. L'azienda ha sviluppato un nuovo ceppo produttivo per il loro sistema ibrido doppio, che dovrebbe aumentare la produzione di seta di oltre il 25% mensilmente. Il loro attuale sistema ibrido singolo BAM-1, introdotto nel 2024, ha mostrato notevoli miglioramenti in termini di robustezza e produzione di seta, raggiungendo la resistenza degli ibridi di seta commerciali cinesi. L'azienda ha accumulato diverse centinaia di chilogrammi di bozzoli nel primo trimestre del 2025 e prevede di includere l'inventario dei bozzoli nei futuri report sul lavoro in corso. KBLB si sta preparando per consegne commerciali a tre grandi marchi globali nella seconda metà del 2025: un marchio di moda di lusso, un'azienda di abbigliamento sportivo di alta gamma e un produttore tra i primi cinque di attrezzature atletiche, tutti impegnati attraverso dichiarazioni o budget approvati.
Kraig Biocraft Laboratories (KBLB) emitió una carta a los accionistas detallando avances significativos en su tecnología de seda de araña. La empresa ha desarrollado una nueva cepa de producción para su sistema híbrido doble, que se espera mejore las tasas de producción de seda en más del 25% mensual. Su sistema híbrido simple BAM-1, introducido en 2024, ha mostrado mejoras sustanciales en robustez y producción de seda, igualando la resistencia de los híbridos comerciales chinos. La compañía ha almacenado varios cientos de kilogramos de capullos en el primer trimestre de 2025 y planea incluir el inventario de capullos en futuros informes de trabajo en progreso. KBLB se está preparando para entregas comerciales a tres grandes marcas globales en la segunda mitad de 2025: una marca de moda de lujo, una empresa de ropa deportiva de alto rendimiento y un productor entre los cinco principales de equipos deportivos, todos los cuales han expresado su compromiso mediante citas o presupuestos aprobados.
Kraig Biocraft Laboratories(KBLB)는 주주들에게 거미줄 기술에서 중요한 진전을 상세히 설명하는 서한을 발행했습니다. 회사는 이중 하이브리드 시스템을 위한 새로운 생산 균주를 개발했으며, 이를 통해 월간 실크 생산량이 25% 이상 증가할 것으로 기대됩니다. 2024년에 도입된 현재의 BAM-1 단일 하이브리드 시스템은 견고성과 실크 생산에서 상당한 개선을 보였으며, 중국 상업용 실크 하이브리드의 내구성과 맞먹는 성과를 보였습니다. 회사는 2025년 1분기에 수백 킬로그램의 고치를 비축했으며, 향후 진행 중인 작업 보고서에 고치 재고를 포함할 계획입니다. KBLB는 2025년 하반기에 세 개의 주요 글로벌 브랜드에 상업적 납품을 준비 중이며, 이들 브랜드는 고급 패션 브랜드, 고성능 스포츠웨어 회사, 그리고 상위 5위 내 운동기구 제조사로, 모두 인용문이나 승인된 예산을 통해 약속을 표명했습니다.
Kraig Biocraft Laboratories (KBLB) a publié une lettre aux actionnaires détaillant des avancées significatives dans leur technologie de soie d'araignée. L'entreprise a développé une nouvelle souche de production pour leur système hybride double, qui devrait améliorer les taux de production de soie de plus de 25 % par mois. Leur système hybride simple BAM-1, introduit en 2024, a montré des améliorations substantielles en robustesse et en production de soie, égalant la résilience des hybrides commerciaux chinois. La société a stocké plusieurs centaines de kilogrammes de cocons au premier trimestre 2025 et prévoit d'inclure l'inventaire des cocons dans les futurs rapports de travaux en cours. KBLB se prépare à des livraisons commerciales à trois grandes marques mondiales au second semestre 2025 : une marque de mode de luxe, une entreprise de vêtements de sport haut de gamme et un des cinq premiers producteurs d'équipements sportifs, tous ayant exprimé leur engagement par des citations ou des budgets approuvés.
Kraig Biocraft Laboratories (KBLB) veröffentlichte einen Aktionärsbrief, der bedeutende Fortschritte in ihrer Spinnseidentechnologie beschreibt. Das Unternehmen hat einen neuen Produktionsstamm für ihr Doppel-Hybridsystem entwickelt, der voraussichtlich die Seidenproduktion monatlich um über 25 % steigert. Ihr aktuelles BAM-1-Einzelhybridsystem, eingeführt im Jahr 2024, zeigte erhebliche Verbesserungen in Robustheit und Seidenproduktion und erreicht die Widerstandsfähigkeit chinesischer kommerzieller Seidenhybride. Das Unternehmen hat im ersten Quartal 2025 mehrere hundert Kilogramm Kokons gelagert und plant, den Kokonbestand in zukünftige Berichte über unfertige Arbeiten aufzunehmen. KBLB bereitet sich auf kommerzielle Lieferungen an drei große globale Marken in der zweiten Hälfte des Jahres 2025 vor: eine Luxusmodemarke, ein hochwertiges Performance-Sportbekleidungsunternehmen und einen der fünf größten Hersteller von Sportausrüstung, die alle ihr Engagement durch Zitate oder genehmigte Budgets bekundet haben.
Positive
  • Development of new spider silk production strain completed on schedule, advancing double hybrid system implementation
  • New double hybrid system expected to improve silk production rates by over 25% per month
  • BAM-1 hybrid system shows robustness comparable to Chinese commercial silk hybrids
  • Several hundred kilograms of cocoon inventory stockpiled in Q1 2025
  • Secured commitments from three major global brands for commercial deliveries in H2 2025
Negative
  • Production affected by seasonal challenges during rainy season
  • 10-30% of silk production typically lost due to diseases and adverse weather conditions
  • Current inventory reporting doesn't reflect total production due to unreeled cocoon stockpile

ANN ARBOR, Mich., June 03, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, issues a letter to shareholders.

KBLB BAM-1 Recombinant Spider Silk Cocoons

Dear Shareholders,

We recently received inquiries from several of our shareholders. In preparing those responses, we realized that we should share the contents with the broader Kraig Labs community. Many had questions related to last week's announcement of the development of the new production strain and the potential for commercial deliveries in 2025.

The development of a new spider silk production transgenic has been a key part of our production roadmap since 2023 and a primary objective of our genetics team during the last 18 months. Our longstanding plans were to field a new strain of silkworm for our double hybrid production system in the Summer of 2025. To be frank, we were unsure whether we could meet that ambitious schedule. We were, therefore, ecstatic to announce that we created another world's first development on schedule. This and many of our other laboratory announcements are not only significant; they're foundational technology building blocks to our success.

Our current single hybrid system, utilizing BAM-1, has already shown massive improvement in robustness and silk production output. The newly announced strain is another significant improvement in our production, moving us a significant step closer to a more powerful double hybrid. The double hybrid model is designed to significantly improve our silk production rate; we expect by as much as 25+% per month, so this is something that we were very excited to share with our shareholders.

We are no longer experiencing the robustness challenges we faced with single-strain rearing. Before the rollout of the BAM-1 hybrid in 2024, our silkworms lacked the robustness to deal with the silkworm diseases and environmental stress that are frequently present in the field. In terms of robustness and disease tolerance, the BAM-1 appears to be on par with the Chinese commercial silk hybrid, which is the gold standard in that region for the production of mundane silk.

Now, this doesn't mean that we are invincible. Globally, between 10% to 30% of all silk production with robust double hybrids is lost due to a handful of diseases and adverse weather conditions. This is just a part of working with these living production systems. It is a fact that is reflected in global silk economics. Since rolling out the BAM-1, we have dealt with these routine challenges and have weathered these events with similar or identical effects as mundane silk producers utilizing the Chinese hybrid. Right now, the region's sericulture operators are in their rainy season, which is typically the worst time for silkworm rearing. Production of our BAM-1 strains and production of mundane silk producers utilizing Chinese hybrids are negatively impacted during this cycle. That is a normal part of silkworm rearing and is something that all silkworm producers encounter as a normal part of the business.

In the past, before we introduced BAM-1, the effects on our silkworms were significantly magnified and effectively stymied our growth. In short, there has been a revolution in our spider silk production technology over the past 14 months due to the introduction of BAM-1 and other improvements in the field and laboratory. As we meet our marks toward the initiation of the double hybrid, we anticipate our gains to accelerate further.

Regarding inventory calculation, our current inventory figures track finished raw reeled silk. In the first quarter of this year, we stockpiled several hundred kilograms of cocoon that are now waiting to be processed into finished silk. The reason inventory did not increase in our financial report was because that report tracked finished silk or material form. After considering these questions, and in light of the fact that we are moving from nominal inventory to larger scale production, we will expand the scope of our work-in-progress (WIP) material inventory to include recombinant spider silk cocoon that has been completed but not reeled. You can expect us to begin adding completed recombinant spider silk cocoon to our WIP to all future inventory balances.

We are 100% focused on the production of spider silk for commercial delivery. Over the last year, we've been able to move faster to deliver on that commitment. As a great example, we are in regular communication with three major Global brands that are standing by to receive their first shipments of materials. The first is an internationally renowned high-end luxury fashion brand that has already accepted a quote from Kraig Labs. The second is a world leader in high-end performance sportswear with an approved budget to buy silk from us. The third is one of the world's top 5 performance athletic equipment producers, looking for spider silk to integrate into their top-performing products. Supplying products to these three entities is the focus of our current production. Currently, we expect to begin deliveries to these customers in the second half of this year. That will be a significant milestone for Kraig Labs, our shareholders, and material science.

I believe the future for Kraig Labs and spider silk has never been brighter, and we thank you for your continued support.

Kim Thompson, CEO

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/afaa22d8-7f0a-4fcb-b905-f58e42ddc46a


FAQ

What is the expected production improvement from KBLB's new double hybrid system?

The new double hybrid system is expected to improve silk production rates by more than 25% per month compared to the current system.

When will Kraig Biocraft (KBLB) begin commercial deliveries of spider silk?

KBLB expects to begin commercial deliveries to three major global brands in the second half of 2025.

How does KBLB's BAM-1 hybrid compare to traditional silk production?

The BAM-1 hybrid shows robustness and disease tolerance comparable to Chinese commercial silk hybrids, which are considered the industry gold standard.

What major brands have committed to purchasing KBLB's spider silk?

Three major brands have committed: a luxury fashion brand, a high-end performance sportswear company, and one of the world's top 5 athletic equipment producers.

How much spider silk inventory does KBLB currently have?

KBLB has several hundred kilograms of cocoon inventory from Q1 2025 waiting to be processed into finished silk.
Kraig Biocraft Laboratories In

OTC:KBLB

KBLB Rankings

KBLB Latest News

KBLB Stock Data

83.16M
784.01M
25.34%
0.01%
Specialty Chemicals
Basic Materials
Link
United States
Ann Arbor